Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

“Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2027” is a recent report generated by MarketResearch.biz, which offers in-depth insights, revenue details, and other vital information regarding the global clinical oncology next generation sequencing (NGS) market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global clinical oncology next generation sequencing (NGS) market report has been segmented on the basis of technology, workflow, end user, and region.

Introduction:

Oncology is the study of medicines that is useful and deals with diagnosis, treatment & prevention of cancer. Next Generation Sequencing (NGS) is alluded to as a non-Sanger based high throughput DNA sequencing innovation. This clinical oncology next generation sequencing is used for characterizing a few present day and progressed sequencing advancements, for instance, Proton/PGM sequencing, Solid sequencing, Roche 454 sequencing, and Illumina (Solexa) sequencing, among several others. Clinical oncology next generation sequencing is used in individual patient cancer management.

Market Dynamics:

Increasing coverage of NGS coupled with improving understanding of the genetic markers of virulence and resistance provided by next generation sequencing are major factors expected to drive growth of the global clinical oncology next generation sequencing (NGS) market. In addition, rising adoption of sequencing-based diagnostics platforms among practicing oncologists, growing R&D funding by government, increasing incidences of cancer are other factors expected to drive growth of the global target market. Furthermore, higher adoption of clinical oncology next generation sequencing technology and platforms in university projects are some of the other factors expected to drive revenue growth of the global clinical oncology next generation sequencing (NGS) market. However, high cost of these technology is the major factor expected to restraint growth of the global target market.

Regional Analysis:

North America market is estimated to account for highest revenue share in the global clinical oncology next generation sequencing (NGS) market over the forecast period, due to strategic initiatives taken up by the governments for these technology in the countries in the region. Asia Pacific market is expected to account for the second-highest revenue share in the global clinical oncology next generation sequencing (NGS) market, due to growing automation in the pre-sequencing protocols in the countries in the region. The market in Europe is projected to register fastest growth rate in terms of revenue due to increasing adoption of clinical oncology next generation sequencing technologies in the countries in the region. Moreover, the markets in Latin America and Middle East & Africa are expected to register moderate growth rate over the forecast period. Revenue from the market in Middle East & Africa is projected to register a CAGR of X.X% in the global clinical oncology next generation sequencing (NGS) market over the forecast period.

Global clinical oncology next generation sequencing (NGS) market segmentation:

By type of technology:

• Whole Genome Sequencing
• Targeted Sequencing & Resequencing
• Whole Exon Sequencing

 By workflow:

• NGS Data Analysis
• NGS Tertiary Data Analysis
• NGS Secondary Data Analysis
• NGS Primary Data Analysis
• NGS Pre-Sequencing
• NGS Sequencing

By end User:

• Hospitals & Clinics
• Pharma & Biotech Entities
• Clinical Research
• Academic Research
• Other Users

 By region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Myriad Genetics, Inc.
• Caris Life Sciences, Inc.
• Illumina, Inc.
• Foundation Medicine, Inc.
• Agilent Technologies
• Genomatix Software GmbH
• Bio-Rad Laboratories
• GATC Biotech
• Oxford Nanopore Technologies Limited
• Pacific Biosciences of California, Inc.
• Macrogen, Inc.
• PerkinElmer, Inc.